

# Amfenac Sodium Hydrate

Catalog No: tcsc0012428



## Available Sizes

Size: 10mg

Size: 50mg



## Specifications

### CAS No:

61618-27-7

### Formula:

$C_{15}H_{14}NNaO_4$

### Pathway:

Immunology/Inflammation

### Target:

COX

### Purity / Grade:

>98%

### Solubility:

DMSO : 150 mg/mL (508.01 mM; Need ultrasonic and warming)

### Observed Molecular Weight:

295.27


## Product Description

Amfenac Sodium Hydrate is a **COX-2** inhibitor.

IC50 & Target: COX-2<sup>[1]</sup>

**In Vitro:** Cells transfected to express COX-2 have a higher proliferation rate than those do not. The addition of Amfenac Sodium Hydrate significantly decreases the proliferation rate of all cell lines. Nitric oxide production by macrophages is inhibited by the

addition of melanoma conditioned medium, the addition of Amfenac Sodium Hydrate partially overcomes this inhibition<sup>[1]</sup>. Results show that Amfenac Sodium Hydrate inhibits the release of B-glucuronidase:  $5 \times 10^{-4}$  M Amfenac Sodium Hydrate inhibits the release of the enzyme 35.3 and 16.3% in the presence of  $10^{-8}$ , and  $10^{-7}$  M FMLP, respectively. Addition of  $10^{-4}$  M Amfenac Sodium Hydrate causes 28.3% inhibition of aggregation of polymorphonuclear leukocytes (PMNs) during incubation for 16 min with  $10^{-8}$  M FMLP<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!